Trial Profile
A Single-blind, Randomized, Unbalanced Crossover Design With 5 Vehicles, 5 Periods, and 5 Sequences, Repeated-doses (With no Ingestion) Study to Assess the Palatability of Eliglustat Prototype Liquid Formulations in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Therapeutic Use
- Sponsors Genzyme Corporation; Sanofi
- 26 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 23 Apr 2015 New trial record